Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D7CH
|
|||
| Drug Name |
TAK-828
|
|||
| Synonyms |
ICMFYVOUDGRBLG-NJMNTPMDSA-N; TAK828F; GTPL9867; TAK-828F; SCHEMBL17390967; SCHEMBL17390969; SCHEMBL17391123; ICMFYVOUDGRBLG-VFHHBZAHSA-N; ICMFYVOUDGRBLG-XVNUGVHUSA-N; compound 10 [PMID: 29510038]; E3V; {cis-3-[(5R)-5-[(7-fluoro-1,1-dimethyl-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridine-6(5H)-carbonyl]cyclobutyl}acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7,8-dihydro-1,6-naphthyridin-6 (5H)-yl)carbonyl)cyclobutyl)acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2
Click to Show/Hide
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 1 | [1] | |
| Company |
Takeda Pharmaceuticals Deerfield, IL
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H32FN3O5
|
|||
| Canonical SMILES |
CC1(CCC2=C1C(=CC(=C2)NC(=O)C3C4=C(CCN3C(=O)C5CC(C5)CC(=O)O)N=C(C=C4)OC)F)C
|
|||
| InChI |
1S/C28H32FN3O5/c1-28(2)8-6-16-13-18(14-20(29)24(16)28)30-26(35)25-19-4-5-22(37-3)31-21(19)7-9-32(25)27(36)17-10-15(11-17)12-23(33)34/h4-5,13-15,17,25H,6-12H2,1-3H3,(H,30,35)(H,33,34)/t15?,17?,25-/m1/s1
|
|||
| InChIKey |
ICMFYVOUDGRBLG-NJMNTPMDSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear receptor ROR-gamma (RORG) | Target Info | Agonist | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.